MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Key facts

Sponsor

Bruno C. Medeiros

Principal Investigator

Bruno de Medeiros, MD

Stanford University

Intervention

MEK inhibitor MEK162(drug)

Enrollment

1 enrolled

Eligibility

18-75 years · All sexes

Timeline

2014 – 2017

Study locations (1)

• Stanford University, School of Medicine, Stanford, California, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute erythroid leukemia

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT00658814
  Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
  National Cancer Institute (NCI)

See all trials for Acute erythroid leukemia →